Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20590135 | 0.98 | HDAC1 (0.37) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL193288 | 0.98 | HDAC1 (0.37) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| Maleic Acid SCHEMBL28227364 | 0.86 | HCAR2 (0.40) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL420985 | 0.86 | TP53 (0.42) | TDP1CYP3A4TSHRCA1CA2 | |
| SCHEMBL22361234 | 0.85 | TSHR (0.46) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL419967 | 0.84 | TP53 (0.50) | CA1TP53FDPSRECQL | |
| SCHEMBL10569914 | 0.83 | CA1 (0.39) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL754171 | 0.82 | TP53 (0.48) | CA1CA2TP53FDPS | |
| SCHEMBL754167 | 0.82 | TP53 (0.48) | CA1CA2TP53FDPS | |
| SCHEMBL27960179 | 0.82 | TP53 (0.48) | CA1CA2TP53FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10466 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4593865-B1 | PHARMACEUTICAL COMPOSITION COMPRISING NFL-TBS40-63 PEPTIDE, VARIANTS OR SALTS THEREOF AND ALANINE | GLIOCURE (FR) | 2026-05-06 | — | — | EP | claimed |
| US-12616694-B2 | Pharmaceutical compositions for subcutaneous administration of levosimendan | TENAX THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026089751-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | Finitus, LLC (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090260-A1 | STABLE ORAL LIQUID COMPOSITIONS | Method Pharmaceuticals, LLC (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | claimed |
| US-20260108460-A1 | STABLE ORAL LIQUID COMPOSITIONS | METHOD PHARMACEUTICALS LLC (US) | 2026-04-23 | — | — | US | claimed |
| EP-1117442-A1 | DRY POWDER ACTIVE AGENT PULMONARY DELIVERY | Inhale Therapeutic Systems, Inc. (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2001019338-A1 | FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE WITH IMPROVED PHARMACOLOGICAL PROPERTIES | PHARMACIA ITALIA S.P.A. (IT) | 2001-03-22 | — | — | WO | claimed |
| WO-2001019339-A1 | FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE AND SULFOALKYL ETHER CYCLODEXTRINS | PHARMACIA ITALIA S.P.A. (IT) | 2001-03-22 | — | — | WO | claimed |
| EP-1067942-A1 | HIGH-ENERGY CYCLODEXTRIN COMPLEXES | Cyclops, EHF. (IS) | 2001-01-17 | — | — | EP | claimed |
| WO-2001001960-A1 | CLEAR OIL-CONTAINING PHARMACEUTICAL COMPOSITIONS | LIPOCINE, INC. (US) | 2001-01-11 | — | — | WO | claimed |
| WO-2001000243-A1 | PHARMACEUTICAL COMPLEX | PFIZER LIMITED (GB) | 2001-01-04 | — | — | WO | claimed |
| US-6123932-A | AN AQUEOUS DEODORANT COMPRISING A CYCLODEXTRIN, A SOLID NONPOLYMERIC GELLANT FREE OF INORGANIC GELLING AGENT AND WATER, USEFUL FOR CONTROLLING MALODORS ASSOCIATED WITH HUMAN PERSPIRATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-26 | — | — | US | claimed |
| WO-2000050007-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-08-31 | — | — | WO | claimed |
| WO-2000015262-A1 | DRY POWDER ACTIVE AGENT PULMONARY DELIVERY | INHALE THERAPEUTIC SYSTEMS, INC. (US) | 2000-03-23 | — | — | WO | claimed |
| WO-1999042111-A1 | HIGH-ENERGY CYCLODEXTRIN COMPLEXES | CYCLOPS, EHF. (IS) | 1999-08-26 | — | — | WO | claimed |